Literature DB >> 1899121

Inhibition of endothelium-dependent relaxations by phorbol myristate acetate in canine coronary arteries: role of a pertussis toxin-sensitive G-protein.

N A Flavahan1, H Shimokawa, P M Vanhoutte.   

Abstract

Activation of protein kinase C by phorbol esters inhibits the endothelium-dependent relaxations evoked by certain stimuli. The release of endothelium-derived relaxing factor can be evoked by a number of distinct subcellular processes, including activation of a pertussis toxin-sensitive G-protein. The aim of the present study was to determine whether or not the inhibitory effect of phorbol esters on endothelial function was associated with inhibition of the pertussis toxin-sensitive pathway. Rings of canine coronary artery were suspended for isometric tension recording in organ chambers filled with modified Krebs-Ringer bicarbonate solution, gassed with 95% O2-5% CO2 (37 degrees C). Treatment of arterial rings with pertussis toxin (100 ng/ml) or with phorbol myristate acetate (PMA, 10(-8) M) inhibited the endothelium-dependent relaxations produced by UK 14,304, an alpha-2 adrenergic agonist, leukotriene C4 or by NaF, a direct activator of G-proteins, but did not affect the endothelium-dependent relaxations produced by bradykinin or by A23187. If the arterial rings were first treated with pertussis toxin, PMA (10(-8) M) no longer inhibited the endothelium-dependent relaxations to NaF. Increasing the concentration of PMA (to 3 X 10(-8) and 10(-7) M) caused inhibition of responses to bradykinin. At higher concentrations, PMA (3 X 10(-7) and 10(-6)) also inhibited the relaxations evoked by A23187. The endothelium-independent relaxations evoked by nitroglycerin were not affected by PMA (10(-8) to 10(-6)).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899121

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits.

Authors:  I R Hutcheson; J A Smith; T M Griffith
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

2.  Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation.

Authors:  J F Keaney; Y Guo; D Cunningham; G T Shwaery; A Xu; J A Vita
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

3.  Pertussis toxin-sensitive G proteins influence nitric oxide synthase III activity and protein levels in rat heart.

Authors:  J M Hare; B Kim; N A Flavahan; K M Ricker; X Peng; L Colman; R G Weiss; D A Kass
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

4.  Regulator of G protein signaling 2 deficiency causes endothelial dysfunction and impaired endothelium-derived hyperpolarizing factor-mediated relaxation by dysregulating Gi/o signaling.

Authors:  Patrick Osei-Owusu; Rasna Sabharwal; Kevin M Kaltenbronn; Man-Hee Rhee; Mark W Chapleau; Hans H Dietrich; Kendall J Blumer
Journal:  J Biol Chem       Date:  2012-02-21       Impact factor: 5.157

5.  Calmidazolium, a calmodulin inhibitor, inhibits endothelium-dependent relaxations resistant to nitro-L-arginine in the canine coronary artery.

Authors:  S Illiano; T Nagao; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  Mobilization of intracellular calcium in cultured vascular smooth muscle cells by uridine triphosphate and the calcium ionophore A23187.

Authors:  M Sanchez-Fernandez; G M Katz; G Suarez-Kurtz; G J Kaczorowski; J P Reuben
Journal:  J Membr Biol       Date:  1993-09       Impact factor: 1.843

7.  Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment.

Authors:  Anna Panighini; Emiliano Duranti; Ferruccio Santini; Margherita Maffei; Tommaso Pizzorusso; Niccola Funel; Stefano Taddei; Nunzia Bernardini; Chiara Ippolito; Agostino Virdis; Mario Costa
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.